Abstract 59P
Background
TPX-0131 is an ALK inhibitor developed for non-small lung cancer (NSCLC) patients that became resistant to first-line treatment. At the moment, pharmacokinetic data for TPX-0131 are still sparse. Therefore, we are interested to gain more insight into the pharmacokinetics of TPX-0131. Based on its structure and previously performed experiments with similar ALK inhibitors, TPX-0131 might be a substrate for the ABCB1, ABCG2, and OATP1 transporters and the CYP3A enzyme. Patients suffering from NSCLC often develop brain metastases. Therefore, the penetration of TPX-0131 into the brain is important to evaluate. Our main interest is therefore gaining more insight into the plasma pharmacokinetics (oral exposure) and the extent of brain penetration of TPX-0131.
Methods
An in vitro transwell experiment and in vivo experiments using genetically modified mouse models will be performed. With the use of a transmembrane in vitro transport assay, the potency of human ABCB1, human ABCG2 and murine Abcg2 to transport TPX-0131 will be evaluated. In vivo, the effect of ABCB1, ABCG2, OATP1 and CYP3A on the bioavailability and tissue distribution of TPX-0131 will be assessed. Different knockout and transgenic mouse models will be used for this purpose. The plasma concentration and tissue-to-plasma ratios of the genetically modified mouse models and wild-type mice will be compared after oral administration of 10 mg/kg TPX-0131.
Results
The in vivo data show that the brain concentration and brain-to-plasma ratio of TPX-0131 were significantly increased in the Abcb1a/b;Abcg2-/-compared to the wild-type mice. The plasma levels did not show any significant differences between these strains. Secondly, no significant differences could be observed between the Oatp1a/b-/- and wild-type mice. Furthermore, plasma levels appeared to be similar between Cyp3a-/-, Cyp3AXAV (expressing transgenic human CYP3A4 in liver and intestine in Cyp3a-/- background) and wild-type mice.
Conclusions
TPX-0131 might be a substrate for the ABCB1 and ABCG2 transporters. However, TPX-0131 is probably not a substrate for the OATP1 transporter(s) or the CYP3A enzyme.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Schinkel Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
86P - Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
Presenter: Noé Herbel
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Clinical features and genetic profile of MDM2-altered solid tumors
Presenter: Julia Tejerina-Peces
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluation of trending drug targets and technologies in current drug development
Presenter: Matteo Repetto
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
Presenter: Jacopo Uliano
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
Presenter: Erika Porubayeva
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - Circulating cell-free DNA fragmentation profiles during systemic therapy of advanced-stage non-small cell lung cancer patients
Presenter: Jelena Milovanovic
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Targeted therapy in pediatric acute myeloid leukemia: An unmet need
Presenter: Banda Teja
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
Presenter: Tania Ghosh(Sarkar)
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract